Cidara Therapeutics Sinks Despite Positive Midstage Results
Cidara Therapeutics shares took a big step back on Monday, despite the firm reporting positive topline results from its Phase 2 Strive clinical trial of its lead antifungal candidate.
All Work
Chris Lange
What to Expect When Oracle Reports After the Close
Oracle is scheduled to release its fiscal third-quarter financial results after the markets close on Monday.
KLA-Tencor Moves to Acquire Orbotech
Orbotech shares saw a handy gain to start the week, after it was announced that KLA-Tencor had entered into a definitive agreement to acquire the firm.
Why Canadian Solar Is Higher Despite Mixed Q4 Results
Canadian Solar released mixed fiscal fourth-quarter financial results before the markets opened on Monday.
Is Netflix Encouraging Smoking?
Smoking in media and movies have prompted smoking in society for the past nine decades. While this has been curtailed in recent decades, new avenues for media, like Netflix, have come forward and seem…
Nike, Micron, Oracle and More Major Earnings Coming This Week
24/7 Wall St. has put together a preview of Nike, Micron Technology, Oracle and some of the other top companies reporting their latest results in the coming week.
Why This Analyst Believes Micron Can Keep Up This Explosive Growth
Micron Technology continues to be the star of the chip stocks, with its shares more than doubling in the past year alone. And to add more fuel to the fire, one analyst came out…
Now 2 Nike Executives Resigning Amid Workplace Behavior Investigation
Nike is feeling the heat after it released an internal memo detailing an investigation into workplace behavior, as well as announcing a that a few of its high-level executives would be departing.
Why Qualcomm Is Ousting One of Its Directors
Qualcomm has been fighting to keep itself a standalone public company recently. This means that it has been fighting off all threats to its solidarity, from both external and internal forces.
Even More Biopharma Catalysts Coming Through the End of March
Here, 24/7 Wall St. has included a calendar of some of the biggest companies expecting clinical trial and FDA updates for the rest of March.
Friday’s Biggest Winners and Losers in the S&P 500
Friday was a fairly positive day for the broad U.S. markets. The Dow continued its recovery from the big drop on Wednesday. The S&P 500 and Nasdaq also moved higher on the day if…
Nike Executive Steps Down Amidst Workplace Behavior Investigation
Nike was under fire on Friday following an internal memo and a change in its senior executive management that may or may not be connected.
What’s So Great About Adobe Q1 Earnings
Shares of Adobe Systems hit all-time highs following its most recent earnings report, released after the markets closed on Thursday.
Bookies Bet That Tiger Is Back
By the looks of it, Tiger Woods got his groove back. For some this is the return of golf’s messiah, while for others this is a chance to make a quick buck off of…
Why the Future of Jewelry in America Has Very Little Shine
A couple major players in the jewelry industry reported quarterly results this week, and it seems that all that glitters is not gold, or diamonds for that matter.
Why Broadcom Earnings Aren’t Enough
Broadcom reported its most recent quarterly results after the markets closed on Thursday.
Thursday’s Biggest Winners and Losers in the S&P 500
Thursday was a relatively positive day for the broad U.S. markets. The main highlight was that the Dow made a slight recovery from its big drop on Wednesday. However, the S&P 500 and Nasdaq…
What to Expect When Broadcom Reports After the Close
Broadcom is scheduled to release its fiscal first-quarter financial results after the markets close on Thursday.
How Much Americans Are Really Gambling on March Madness
Americans are expected to wager over $10 billion for this year’s March Madness. But how much of that $10 billion will be wagered legally?
Alexion Wins Big in Late-Stage Trial
Alexion Pharmaceuticals watched its shares make a solid gain on Thursday after the firm announced positive results from its late-stage trial of ALXN1210.